We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Xeomin

News List

Vensica Therapeutics Partners with Merz americanpharmaceuticalreview
August 12, 2021
Vensica Therapeutics, a clinical stage biopharmaceutical company, announced that it has signed a strategic collaboration agreement with Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins.
FDA Approves Broadened Indication for Xeomin (incobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in Adult Patients drugs
May 15, 2019
FDA Approves Broadened Indication for Xeomin (incobotulinumtoxinA) as First-Line Treatment for Blepharospasm (Involuntary Blinking) in Adult Patients.
FDA Approves Xeomin americanpharmaceuticalreview
July 11, 2018
Merz North America announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea
FDA approves drug for excessive drooling pharmatimes
July 04, 2018
Merz Neuroscience’s Xeomin has become the first agent to be approved by the US Food and Drug Administration to treat excessive drooling.